Background: Nasopharyngeal carcinoma (NPC), endemic to Southern China and Southeast Asia, presents significant clinical challenges. Immune checkpoint inhibitors (ICIs) have transformed NPC treatment but carry risks of immune-related adverse events (irAEs). Existing meta-analyses lack NPC-specific data, hindering targeted safety guidance.Methods: This systematic review and meta-analysis, registered with PROSPERO (CRD420251003062), followed PRISMA guidelines. We searched PubMed, Embase, and Web of Science up to March 31, 2025, including all registered clinical trials of ICIs in NPC patients reporting irAEs. Meta-analysis was employed to calculate all grade and ≥3 grade irAE incidence rates. Pooled analysis was applied to delineate the cumulative number of cases for all kinds of irAE and the causes of death attributed to irAEs in patients with NPC.Findings: A total of 27 clinical trials were included in the meta-analysis. The pooled incidence of all-grade irAEs in 2296 patients was 69.1% (95% CI: 50.4%-80.7%), and that of grade 3 or higher irAEs in 2459 patients was 8.1% (95% CI: 6.1%-10.6%). Subgroup analyses revealed that there were no significant differences in the incidence of irAEs based on disease stages, lines of treatment, and combination treatment strategies. The main types of all-grade irAEs with an incidence rate greater than 1% are as follows: hypothyroidism (22.4%), rash (10.7%), pruritus (3.6%), increased aspartate aminotransferase (1.9%), increased alanine aminotransferase (1.8%), fatigue (1.6%), anemia (1.6%), pneumonia (1.5%), and hyperthyroidism (1.0%). A total of 17 patients died due to irAEs. Among these, sepsis was the most common cause of death, followed by pneumonitis.Interpretation: This meta-analysis provides a comprehensive overview of irAEs in NPC patients treated with ICIs. These NPC-specific data emphasize the importance of vigilant monitoring for endocrine, cutaneous, and severe pulmonary or infectious complications to balance the efficacy and safety of ICIs.